Moderna (MRNA)

Moderna was the #1 US VolumeSurge pick on Wednesday 19 Aug with a record +177% single-day surge to $174.38 on $32.3B of turnover — the largest daily move in its history. The trigger: its personalized mRNA cancer vaccine (Intismeran / "autogene"), developed with Merck and combined with Keytruda, hit both primary endpoints in a Phase 3 melanoma trial of 1,100+ high-risk patients after complete resection. The readout not only validates Moderna's oncology platform but lifted the entire vaccine complex (Merck +12.6%, BioNTech +22%), and it arrived at a moment when Healthcare is the dominant sector across both the HK (17/50) and US screeners.

Financial Snapshot

COVID vaccine revenue has collapsed from the 2021–22 peak; FY2025 GAAP net loss was $(2.8)B (EPS $(7.26)). Q1 2026 net loss was $(1.3)B. Management guides up to 10% revenue growth and GAAP opex reductions in 2026.

Bull vs Bear

Year	Revenue	Rev Growth	Op Margin	Net Income
2021	$18.5B	+2,200%	~72%	+$12.2B
2022	$19.3B	+4%	~49%	+$8.4B
2023	$6.85B	-64%	~-61%	-$4.7B
2024	$3.24B	-53%	~-102%	-$3.6B
2025	$1.92B	-41%	~-142%	-$2.8B

✅ Bull Case

Platform validation, not just one drug: melanoma success de-risks the personalized mRNA neoantigen approach, with trials already running in NSCLC, bladder and renal cell carcinoma — a potential multi-billion-dollar oncology franchise beyond COVID.
Keytruda combo economics: pairing with Merck's standard-of-care immunotherapy gives a ready commercial channel and Merck co-investment; milestone/royalty economics could transform a revenue base that shrank to ~$1.9B.
Repositioning + short squeeze: a ~$25B→~$69B re-rating plus $5.5B of short-seller losses suggests continued covering; R&D spend is already down ~24% YoY toward the 10%-growth/opex-cut plan.

🔴 Bear Case

Valuation runs far ahead of sales: ~$69B cap on ~$1.9B trailing revenue (~36x sales) with years of losses; approval, reimbursement and commercial ramp are still years out, and overall-survival data is not yet shown.
Personalized manufacturing is hard: each vaccine is patient-specific (bespoke neoantigen design + mRNA manufacturing), raising cost, turnaround-time and margin questions vs. off-the-shelf drugs.
Base business still shrinking: COVID revenue fell another ~41% in 2025; even with 10% growth guidance the near-term P&L is deeply negative, and a binary miss (OS readout or regulatory delay) could unwind much of the move.

Verdict

A genuine platform-defining moment — the first late-stage validation of a personalized mRNA cancer vaccine — but the +177% move has already priced in a large share of the upside while the underlying business remains a loss-making COVID vaccine maker in secular decline. It's a compelling story to watch, but at ~$69B the risk/reward is skewed after a ~2.8x vertical move; I'd want overall-survival data and an actual regulatory filing before owning it here.

Why This Company Now

Financial Snapshot

Bull vs Bear

✅ Bull Case

🔴 Bear Case

Verdict